Josh Wolfe
Independent DirectorMr. Joshua Wolfe, also known as Josh, serves as Co-Founder of Lux Capital Management, LLC, which he co-founded in 2000 and also serves as Partner since May 2025. His responsibilities include investments in physical and life sciences. At the firm, he also served as Managing Partner & MD until May 2025, as Founding Partner and as Managing Partner. He has co-founded numerous Lux companies from scratch. Mr. Wolfe holds numerous other current roles. He serves as Independent Director at Shapeways Holdings, Inc. since July 1, 2022; he previously served as the company's Independent Chairman from September 29, 2021 to July 1, 2022 and was an Independent Director at the company from May 2012. He is Co-Founder of Kurion, Inc., where he serves as Director, Advisor and Member of the Advisory Board and also served as Chairman and Chairman of Advisors. He is Co-Founder of The NanoBusiness Commercialization Association and serves as Coordinator for the Institute of Molecular Manufacturing's Prize in Computational Nanotechnology. He served as Independent Director at Eikon Therapeutics, Inc. since 2022 until July 31, 2026. He is also Co-Founder of Coney Island Prep and serves as Chairman of the Board of Trustees. His current directorships include Santa Fe Institute Of Science Inc. since May 3, 2015, Aera Therapeutics Inc., Aira Tech Corp., Angstrom Publishing, Cajal Neuroscience, Inc., Crystal IS, Inc., Kallyope, Inc., Lux Research, Inc., Osmo Labs, PBC, Reflect Orbital Inc., Strateos, Inc., Varda and Variant Bio, Inc. He is also Co-Owner of Lux Encore Sponsor, LP. His prior experience includes serving as Managing Director of Angstrom Partners LLC. He was an Executive Officer at Merrill Lynch & Co., Inc., Citigroup CIB and Prudential Equity Group, LLC. He also worked in Salomon Smith Barney's Investment Banking Group, at Merrill Lynch & Co., Inc. on its Financial Futures and Options and Government strategy desk and at Prudential Securities in its Municipal Finance department. His prior directorships include Gandeeva Therapeutics, Inc. until June 2024, Creyon Bio, Inc. from April 2023 to 2024, Atavistik Bio, Inc. until 2024, 3Scan, Inc. from January 27, 2015, Kymeta Corporation and Silicon Clocks, Inc. He has been invited by the White House, Capitol Hill and the Canadian Government to advise government organizations on funding strategies and on nanotechnology and emerging technologies. He is the author of the ‘Nanotech Report’ and an Editor of the monthly Forbes/Wolfe Emerging Tech Report. He has also conducted and published research in Cell Vision and The Journal of Leukocyte Biology. He is a lecturer at MIT, Harvard, Yale, Cornell, Columbia and NYU. He has been actively involved with the East Harlem School at Exodus House for several years. He received a B.S. in Economics & Finance from Cornell University.
Positions
- Company NameShapeways Holdings, Inc.Stock CodeSHPWQPositionIndependent DirectorColleagues
- ARAlberto RecchiCFO & Director
- LCLeslie C. G. CampbellIndependent Chairman
- MVMarleen VogelaarCo-Founder & CEO
- JWJules WitteChief Operating Officer
- RSRobert SchouwenburgChief Technology Officer
- TSTiago Sao JoseHead of Engineering
- RKRyan KearnyIndependent Director
- CMChristine Marie GorjancIndependent Director
